The Department of Defense Pharmacy & Therapeutics Committee's mission is to uniformly, consistently, and equitably provide appropriate drug therapy to meet the clinical needs of DOD beneficiaries in an effective, efficient, and fiscally responsible manner.
To learn more, please see the December 2004 Health Affairs Policy 04-032, TRICARE Pharmacy Benefit Formulary Management (clarified Mar. 22, 2005).
DOD P&T Committee Meeting Schedule
View DOD P&T Meeting Minutes See Archived Meeting Pages
Nov. 6-7, 2024
Uniform Formulary Request for Quote Information
Uniform Formulary Request for Quote Information
- UF BPA & UF ADP RFQ Documents Posted: July 18, 2024
- Pre-Proposal Teleconference: July 24, 2024 at 1 p.m. CT
- UF BPA & UF ADP Class Quotes Due: Sept. 19, 2024 at 12 p.m. CT
*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.
| Class Review |
Designated Newly Approved Drugs |
Utilization Management |
- MIGRAINE AGENTS - ORAL CGRP:
-
Nurtec ODT
-
Qulipta
-
Ubrelvy
- TARGETED IMMUNOMODULATORY BIOLOGICS - INTERLEUKIN 17 (IL-17):
-
Bimzelx
-
Cosentyx
-
Siliq
-
Taltz
- TARGETED IMMUNOMODULATORY BIOLOGICS - INTERLEUKIN 23 (IL-23):
-
Ilumya
-
Omvoh
-
Skyrizi
-
Stelara
-
Tremfya
|
|
|
Aug. 7-8, 2024
Uniform Formulary Request for Quote Information
Uniform Formulary Request for Quote Information
- UF BPA & UF ADP RFQ Documents Posted: April 22, 2024
- Pre-Proposal Teleconference: April 24, 2024 at 1 p.m. CT
- UF BPA & UF ADP Class Quotes Due: June 13, 2024 at 12 p.m. CT
*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.
| Class Review |
Designated Newly Approved Drugs |
Utilization Management |
- ANTILIPIDEMICS-1 AGENTS - NON-STATIN and COMBOS:
- ANTILIPIDEMICS-1 AGENTS - STATINS:
-
Altoprev
-
Atorvaliq
-
Ezallor Sprinkle
-
Flolipid
-
Zypitamag
- LEUKEMIA and LYMPHOMA AGENTS - BRUTON TYROSINE KINASE INHIBITORS:
-
Brukinsa
-
Calquence
-
Imbruvica
- Jaypirca
|
-
Duvyzat
-
Humira (Cordavis)
-
Iqirvo
-
Libervant TM
-
Myhibbin
-
Ojemda
-
Opsynvi
-
Rextovy
-
Rezdiffra
-
Simlandi
-
Sitagliptin/metformin
-
Spevigo
-
Tyenne
-
Voydeya
-
Winrevair
-
Xolremdi
|
|
May 1-2, 2024
Uniform Formulary Request for Quote Information
Uniform Formulary Request for Quote Information (New Drug Class)
- UF BPA & UF ADP RFQ Documents Posted: Jan. 31, 2024
- Pre-Proposal Teleconference: Jan. 31, 2024 at 1 p.m. CT
- UF BPA & UF ADP Class Quotes Due: Mar. 21, 2024 at 12 p.m. CT
*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.
| Class Review |
Designated Newly Approved Drugs |
Utilization Management |
- INSULINS - BASAL:
-
Basaglar Kwikpen U-100
-
Basaglar Tempo Pen U-100
-
Insulin Degludec
-
Insulin Degludec Pen U-100
-
Insulin Degludec Pen U-200
-
Insulin Glargine
-
Insulin Glargine Solostar
-
Insulin Glargine-YFGN
-
Lantus
-
Lantus Solostar
-
Levemir
-
Levemir Flexpen
-
Levemir Flextouch
-
Rezvoglar Kwikpen
-
Semglee
-
Semglee-YFGN
-
Semglee-YFGN Pen
-
Semglee Pen
-
Toujeo Max Solostar
-
Toujeo Solostar
-
Tresiba
-
Tresiba Flextouch U-100
-
Tresiba Flextouch U-200
- WEIGHT LOSS AGENTS - NA:
-
Apidex-P
-
Contrave
-
Lomaira
-
Orlistat
-
Qsymia
-
Saxenda
-
Wegovy
-
Xenical
-
Zepbound
- PULMONARY II AGENTS - INHALED CORTICOSTERIODS:
|
-
Agamree
-
Alvaiz
-
Bosulif
-
Eohilia
-
Fabhalta
-
Filsuvez
-
Iwilfin
-
Rivfloza
-
Vevye
-
Wainua
-
Xolair Auto-injector
-
Zilbrysq
-
Zituvio
-
Zoryve
-
Zymfentra
|
|
Feb. 7-8, 2024
Uniform Formulary Request for Quote Information
- UF BPA & UF ADP RFQ Documents Posted: Oct. 26, 2023
- Pre-Proposal Teleconference: Nov. 8, 2023 at 1 p.m. CT
- UF BPA & UF ADP Class Quotes Due: Dec. 21, 2023 at 12 p.m. CT
*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.
| Class Review |
Designated Newly Approved Drugs |
Utilization Management |
- GROWTH STIMULATING AGENTS - NA:
-
Genotropin
-
Humatrope
-
Ngenla
-
Norditropin Flexpro
-
Nutropin AQ Nuspin
-
Omnitrope
-
Saizen
-
Saizen-Saizenprep
-
Serostim
-
Skytrofa
-
Sogroya
-
Zomacton
|
-
Abrilada
-
Augtyro
-
Bimzelx
-
Cabtreo
-
Coxanto
-
Entyvio
-
Fruzaqla
-
Jesduvroq
-
Jylamvo
-
Likmez
-
Motpoly XR
-
Ogsiveo
-
Ojjaara
-
Omvoh
-
Truqap
-
Velsipity
-
Voquezna
-
Xalkori
-
Xphozah
-
Zepbound
-
Zurzuvae
|
- PRIOR AUTHORIZATION UPDATES:
-
Adbry
-
Besremi
-
Cosentyx
-
Enbrel
-
Forteo
-
Jaypirca
-
Lidocan
-
Lynparza
-
Mektovi
-
Nubeqa
-
Orencia
-
Pokonza
-
Rozlytrek
-
Tibsovo
-
Venclexta
-
Voxzogo
-
Welireg
-
Xtandi
-
Yonsa
-
Zoryve
-
Zytiga
|
If the DOD P&T Committee is unable to complete an evaluation of any of the drug classes, the Committee will continue its efforts at the next meeting.
Subject to Change Disclaimer
The Defense Health Agency reserves the right to change the classes, sub-classes and/or designated new drugs, and other requirements, of whatever kind, affecting solicitations. The provisions of this table do not constitute a contract, express or implied, between the DHA and manufacturer or eligible bidder.